Introduction have established HIV-1 packaging cells stably transfected Murine retrovirus vectors have been the vehicle of choice
with an HIV-1 vector, and shown that the virions profor gene delivery for a variety of disease models, includduced by these cells were replication-incompetent, but ing HIV infection. Several phase 1 clinical protocols that able to transduce CD4 + cells with titers of 10 4 to 10 5 . We have been initiated to evaluate the safety and efficacy of have now replaced the HIV-1 vector with an HIV-2 vecdifferent anti-HIV genes involve transduction of CD4 + T tor in order to minimize possible recombination between cells by murine retrovirus vectors ex vivo, followed by vector and packaging cells. This attempt was based on infusion of the gene-altered cells into autologous or synthe assumption that HIV-2 RNA would be packaged by geneic recipients. 1 Although such studies are important the HIV-1 packaging cell line, as SIV RNA was shown to for proof of concept, the use of murine virus vectors be encapsidated into HIV-1 particles. 3 In this article, we imposes several limitations: the need for ex vivo manipureport three new steps forward in the utilization of HIVlations because of the lack of targeting and/or sufficiently derived tools for gene therapy: (1) the packaging of an high titers of the vectors, the inability to transduce non-HIV-2 vector by an HIV-1 packaging cell line to generate dividing cells, eg macrophages, and the need to activate a relatively high titer stable producing line; (2) the gener-T cells prior to transduction, which may also induce ation of a Rev-independent vector through insertion of a apoptosis of these cells. An HIV vector has the obvious constitutive transport element of a simple D-retrovirus; advantages of targeting CD4
+ cells, including macroand (3) the transduction of human primary macrophages phages, as well as being able to enter and persist in nonby this stable HIV-derived gene delivery system. dividing T cells. These features, combined with further advantages that include cotrafficking of the vector and virus in the same cellular compartments and the possiResults bility for the vector to be rescued and propagated by wild-type virions during the infection of transduced cells, Design of a rev-independent HIV-2 vector may allow direct in vivo delivery of therapeutic genes for Part of the 5′ gag sequences have been shown to be HIV-infected patients. In order to obtain a stable system required for optimal packaging of HIV vectors. 4 Since that can be fully characterized and utilized for human these sequences contain the inhibitory sequence (INS-1), gene therapy, we directed our efforts to developing an stability and expression of the vector RNA is Rev-depen-HIV-1 packaging cell line that could generate relatively dent. 5 To counteract the inhibitory effect of INS- corresponding element from simian retrovirus type 1 and the PCR (Figure 2b) were negative for cells exposed to up to 1 ng of p24 equivalent of VR-4 virions. On the (SRV-1). Both the MPMV and SRV-1 elements are also able to efficiently substitute for Rev in the expression of contrary, cultures exposed to only 1 pg of p24 equivalent of wild-type HIV-1-MN were positive in both assays. No Gag/Pol and Env proteins from subgenomic constructs. Therefore we have replaced the RRE sequence of our evidence of HIV infection was detected in the VR-4 transduced cells even after an additional month of cul-HIV-2 vector by the MPMV element. To create this new HIV-2 vector (Figure 1 ), we deleted a gag-env fragment ture with fresh Molt4/8 cells (Figure 2c ). The HIV-2 vector remained intact after transfer into HeLa-T4 cells, as in the molecular clone HIV-2-KR and replaced it with two elements: the SL3-gpt cassette described previously for verified by Southern blot hybridization (data not shown). our HIV-1 vector, 2 and the MPMV CTE PCR amplified Transduction of human monocyte-derived primary from the clone SRV-3 (obtained from P Luciw, University macrophages of California, Davis). Introduction of the CTE sequence
We next tested the capacity of our gene delivery system into a gag + rev − vector conferred constitutive gag to transduce primary human macrophages. Monocytes expression to a level of about 50% of wild-type (data were isolated from peripheral blood mononuclear cells of not shown).
healthy volunteers by adherence to fibronectin, and cultured for 10 days in the presence of GM-CSF to allow Packaging of the HIV-2 vector in 422 cells maturation into macrophages. The macrophages were This HIV-2 vector, VR, was then transfected into the 422 then selected for adherence to plastic and exposed to the cells and mycophenolic acid-resistant cells were selected.
supernatant of 422 cells stably transfected with either A resistant cell line, VR-4, was further characterized.
the HIV-1 vector, V653gpt, or the HIV-2 vector, VR The filtered supernatant produced by VR-4 was used to ( Figure 1 ). As a negative control, we used the Moloney transduce HeLa-T4 cells. After 4 weeks of selection in the murine leukemia virus (MoMLV) vector LNL-6 packaged presence of mycophenolic acid, the number of surviving by the amphotropic-murine leukemia virus-derived cell HeLa-T4 cells was counted. As shown in Table 1 , VR-4 line PA317, 8 or HeLa CD4 − cell cultures. The transduccell supernatant contains around 10 4 transducing units ing cell supernatants were first treated with DNase to per milliliter. As negative controls, we have verified that eliminate any DNA contamination. Their titers ranged supernatants from 422 cells or VR-transfected HeLa from 10 4 TU/ml for the HIV vectors to 10 5 TU/ml for the cells were unable to transduce HeLa-T4 cells (Table 1) .
MoMLV vector. After a 30-min exposure to these superMoreover, the gene transfer is CD4-dependent: Hela natants, the macrophages were washed extensively and CD4 − cells could not be transduced with the VR-4 cell either lysed for PCR analysis (day 0) or further cultured. supernatant (Table 1 ). We next investigated the possible After 1, 3 and 7 days, cell cultures were washed again production of replication-competent HIV by VR-4.
and lysed for analysis. At the end of the culture, the cell Quadruplicate cultures of Molt4/8 cells were exposed lysates were submitted to PCR using gpt-specific oligonueither to VR-4 or to wild-type HIV-1-MN virions. After cleotides for the HIV vectors and Neo R -specific a month in culture, the Molt4/8 cells were analyzed for oligonucleotides for the murine vectors. Both of these HIV antigen expression and for the presence of HIV DNA primer pairs hybridized at the same optimal temperature sequence. Both the p24 antigen capture assay, which and have comparable sensitivity. Figure 3 shows that the recognizes both HIV-1 and HIV-2 proteins (Figure 2a) HIV-1 and HIV-2 vectors, but not the MoMLV vector, were able to transduce the macrophage cultures. A gpt sequence that was not detectable at day 0, was detected genome, we performed Alu-LTR PCR as previously described. 9 Alu sequences are repetitive sequences dis-seminated throughout the eukaryotic genome. Using an oligomer specific for Alu sequence and an antisense LTR primer, we aimed to amplify the junction fragments at the sites of integration of the HIV vector. As HIV integrates at multiple sites, the sizes of these PR fragments should be variable from cell to cell. This prediction is consistent with the Southern blot of the Alu-LTR PCR products (Figure 4 ), which revealed a smear of hybridization upward of 600 bases (distance of the primer from the 5′ border of the LTR) in lysates of macrophages obtained 4 days after transduction. No hybridization was observed when the Alu-LTR PCR was performed on cell lysates collected at day 0 (30 min after exposure of the cells to the virions), ie before any integration of HIV vector into the macrophage genome was expected to have occurred. DNA from HeLa-CD4 cells stably transduced by the same vector showed the same hybridization pattern as the macrophages at day 4 (data not shown).
Discussion
Although gene therapy is a promising new tool in molecular medicine, the pace of implementation is still stalled by a number of technical shortcomings, a major one being the limited repertoire of gene delivery vectors for appropriate target cells. For example, stable integration of transgenes into nondividing cells has been difficult if not impossible with conventional gene vectors.
Since lentiviruses have the unique capability of infecting nondividing cells, they are naturally attractive candidates for vector development. Naldini et al 10 recently showed that a VSV-G pseudotyped HIV-1 vector, generated by transient cotransfection of vector DNA, an env-anddeleted HIV-1 genome and the VSV-G expression plasmid, was able to transduce macrophages in vitro and mouse neurons in vivo. Such studies have piqued the interests of investigators engaged in gene therapy for a wide spectrum of human diseases. However, because of safety issues, the first test case for the use of an HIV vector will clearly be the HIV infection model. Furthermore, HIV vectors have additional advantages for delivering anti-HIV genes. In addition to its natural exquisite targeting into the very cells that the virus infects, namely, T cells, macrophages and dendritic cells, such vectors can be viewed as defective, interfering particles that cotraffic with HIV and can be rescued, amplified and disseminated by helper HIV in vivo. 11 Furthermore, HIV as well as HIV-derived vectors, can infect quiescent T cells, and the preintegration complex can survive for long periods prior to T cell activation and subsequent integration. ).
14-19 gene ␤-actin was carried out on the same cells (lower panel). Noninfected
Recently, we derived a cell line, 422, by transfecting 
able to transduce CD4
+ cells with a titer of 10 4 to 10 5 transducing units per milliliter. 2 In this study, we have replaced the HIV-1 vector with an HIV-2 vector to limit 
and 7 days) after exposure to V653gpt (HIV-1) or VR-4 (HIV-2) virions, and submitted to PCR using gpt-specific oligonucleotides (upper panel, left). HeLa CD4 − cells were used as a negative control for transduction. PCR was performed on cells stably transfected with the V653gpt plasmid (gV cells) and only buffer as positive and negative controls, respectively. In parallel, genomic DNA of macrophages and HeLa cells exposed to LNL-6/MoMLV particles were analyzed for the presence of the murine vector (PCR specific for the Neo R gene) at day 0 and day 7 (upper right panel). As an internal control, the phosphodehydrogenase gene (PDH) was amplified by PCR in all the cell lysates (lower panel).
sequences in the viral RNA may be involved. 20 Although the primary sequences of the HIV-1 and HIV-2 major packaging signals differ, it is possible that structural similarities exist, which allow cross-packaging at the RNA level. Rizvi et al 3 reported that SIV-RNA, which contains a major packaging signal in the 5′ leader sequence upstream of the major splice donor, can also be encapsidated into HIV-1 particles. Our results showed that an HIV-2 vector which contains minimal viral sequences is also efficiently packaged by HIV-2 proteins.
We confirmed the ability of the MPMV CTE to substitute for Rev-RRE interaction in the context of the HIV-2 vector. The advantages of a Rev-independent vector are two-fold. First, since expression of the vector RNA is constitutive, the rev gene can be ultimately deleted from the packaging plasmid to increase the safety of the system further. Second, expression of a transgene (eg an antiviral gene) within the vector may still be tatinducible, but would occur early after infection since accumulation of Rev is not required. Third, this rev-independent vector may be used to deliver anti-rev genes, eg RRE decoys or transdominant mutant Rev proteins.
We also presented the first description of transduction of human macrophages using a stable gene delivery system. This property was ensured by the choice of the HIV-1-MN clone as the packaging plasmid. In contrast to the monocytes/macrophages) as well as a complete vpr gene. 19 It has been shown that while the env gene contributes to macrophage tropism at the level of virus entry, 21 any risk of homologous recombination with the HIV-1 the matrix protein and vpr enable HIV-1 infection of nonpackaging plasmid. We also abolished Rev dependence dividing cells by permitting the nuclear import of the of the vector RNA by insertion of a constitutive transport preintegration complex. 22, 23 element derived from a type-D retrovirus. We showed In addition to lineage-specific targeting of T lymphothat this novel HIV-2 vector was efficiently packaged in cytes and macrophages, HIV vectors may also be enlisted 422, and that the resultant vector particles were able to to solve another hurdle in gene therapy, namely, the transduce primary human monocyte-derived macrotransduction of hematopoietic stem cells. Although phages.
MoMLV vectors can clearly transduce hematopoietic proThe HIV-2 packaging signal has been less characterized genitor cells which can give rise to both mature T cells than its HIV-1 counterpart. The sequence located and macrophages (Ref. 24 and our unpublished data with between the major splice donor and the ATG initiator of gag is required for HIV-2 RNA packaging, but additional M Rosenzweig, P Johnson and M Heusch), gene transfer into the pluripotent stem cells is extremely inefficient.
25
ture assay (Coulter, Miami, FL, USA) on the cell supernatant for each viral input. PCR was also performed on One possible explanation is that stem cells may not be actively dividing most of the time. 26 An HIV vector the cell lysates using gag-specific oligonucleotides as described. 2 To assess the noninfectivity of the VR-4 pseudotyped with an envelope (eg VSV-G) that allows entry into stem cells may mediate stable gene transfer virions further, supernatants of the 4-week culture of cells exposed to 1000 pg of virus were inoculated into a into this refractory target cell population. If so, the rationale for using HIV vectors for gene therapy against HIV fresh culture of Molt4/8 cells and the production of p24 antigen was monitored by the same ELISA kit. becomes even more compelling.
Macrophage transduction

Materials and methods
Macrophages were cultured as described by Kornbluth et al. 28 Briefly, after isolation of peripheral blood mono-HIV-2 vector construction nuclear cells (PBMC) by centrifugation over FicollThe HIV-2 vector was generated from the HIV-2-KR Hypaque, monocytes were isolated by adherence to fibclone 27 by deleting a BamHI-BamHI fragment that spans ronectin (Gibco-BRL, Grand Island, NY, USA). Twentythe 3′ sequences of gag to the 5′ region of env. This fragfour-well plates were incubated for 1 h at 37°C with ment was replaced by the CTE from a type D retrovirus, 2 mg/ml per well of fibronectin (Gibco-BRL) in Hank's SRV-3.
6 CTE sequences were amplified by PCR from the balanced salt solution, and washed. Two and a half plasmid SRV-3 using the following oligomers: 5′ million PBMC were incubated in 1 ml of RPMI sup-CGGGGATCCCACCTCCCCTGTGAGCTAGACTGG; 3′ plemented with antibiotics, 10% FCS, and 10% AB human TCAGATCTCAAGAGCGGGAAACATTCGCG. The PCR serum (Gibco-BRL), for 24 h at 37°C in each well of the fragment was digested with BamHI and BgIII, and fibronectin-coated plates. Nonadherent cells were then inserted in the HIV-2-KR backbone (plasmid 53RM340).
removed by washing, and adherent cells were cultured in To create the VR vector, p53RM340 was linearized with the same medium supplemented with 4 ng/ml of human BamHI, and ligated with the SL3-gpt cassette which was recombinant granulocyte-macrophage colony-stimulatreleased from the HIV-1 vector V653gpt (Figure 1 ) by ing factor (GM-CSF; Gibco-BRL). After 10 days of this BamHI digestion. The gpt cassette contains the gene treatment, monocytes differentiate into mature macrocoding for the xanthine-guanine phosphoribosyl tranferphages which are 100% nonspecific esterase-positive. ase (gpt), driven by the murine retroviral LTR SL3.
These cultures were washed five times before transduction. Vector supernatants used for transduction were Transfection of 422 cells treated for 1 h at 37°C with DNase I (Gibco-BRL), and The HIV-1 packaging cell line was transfected with the filtered (pore size 0.22 mm). One hundred microliters of HIV-2 vector by the calcium-phosphate method, as the filtrate was added to the macrophage cultures for described previously. 2 After 48 h, cells were selected in 30 min at 37°C. Then the macrophages were washed Dulbecco's modified Eagle's medium (DMEM) supanother five times, and harvested at days 0, 1, 3 or 7 by plemented with 10% dialyzed fetal calf serum (FCS), scraping into 25 ml of 100 mm KCl, 10 mm Tris HCl 250 g/ml xanthine, 15 g/ml hypoxanthine, 10 g/ml (pH 8.3), 2.5 mm MgCl 2 , lysed in 10 mm Tris HCl thymidine, 2 g/ml aminopterin, 25 g/ml mycophen-(pH 8.3), 2.5 mm MgCl 2 , 1% Tween 20, 1% NP40, and olic acid, 150 g/ml of L-glutamine, and antibiotics (gpt treated with proteinase K. The cell lysates were submitmedium). After a 4-week selection, a resistant cell line, ted to PCR as in the infectivity assay. Detection of the gpt YVR-4, was isolated and characterized.
gene was performed with the oligomers: 5′ AGCTAC-GATCACGACAACCA, 3′ ATCAACCAGCGGACGACTransduction CAG. Detection of the Neo R gene utilized the following One hundred microliters of filtered VR-4 cell superoligomers: 5′ TCACTGAAGCGGGAAGGGACTG, 3′ natant (pore size 0.22 mm) was supplemented with GCAATATCACGGGTAGCCAACG. As a positive con-8 g/ml polybrene, and added to 30% confluent HeLatrol, PCR was performed on the same cellular extracts T4 cultivated in a six-well plate (Costar, Cambridge, MA, using oligonucleotides specific for the cellular gene phos-USA). After a 1-h incubation under agitation, 1 ml of pho-dehydrogenase: 5′ GGTATGGATGAGGAGCTGGA, 3′ DMEM supplemented with 10% FCS and antibiotics was CTTCCACAGCCCTCGACTAA. The PCR fragments added, and the cells were cultured for 2 days. At that were analyzed by Southern blot assay. The PCR products time transduced cells were selected in gpt medium. After were size-fractionated by electrophoresis, blotted on to a 4 weeks, mycophenolic acid-resistant cells were counted GeneScreenPlus nylon membrane (NEN, Boston, MA, under an inverted optical microscope.
USA) by salt transfer, and hybridized with an ␣-32 Plabelled specific DNA fragment. Infectivity assay To test the VR-4 cell supernatant infectivity, 1:10
Alu-LTR PCR To demonstrate the integration of the HIV vector in the dilutions of the supernatant, containing 0.001 to 1000 pg of p24 antigen equivalent of virus, were added to quadtransduced macrophages, cells lysed at 30 min or at 4 days after transduction were submitted to PCR using ruplicate cultures of the highly HIV-infectable Molt4/8 cells in 96-well plates (Costar) in a volume of 200 l. The an oligomer specific for the Alu sequence (5′ GGCACTTTGGGAGGCCAAGG), and an antisense same amounts of wild-type HIV-1-MN were inoculated in parallel into Molt4/8 cell cultures as a positive control.
oligomer specific for the HIV-1 LTR, (3′TTT TCGCGAGCGGCCGCTGCTAGAGATTTTCCACACTG). After 24 days, cells were extensively washed, and cultured for 4 additional days. At that time, the percentage After 3 min at 94°C, 35 cycles were performed: denaturation for 1 min at 94°C, hybridization for 1 min at 60°C, of infected cultures was determined by a p24 antigen cap-
